

**Prof. Viola A. Heinzemann**  
**MD FMH FRANZCOG CORT(GO)**  
**Gynecological Oncologist (SIWF)**



Born 01.11.1969

Married, two children

Citizenship: Swiss, Australian, German

## Education

1990 – 1997 Medical School, Eberhard-Karls-University of Tübingen, Germany

1997 International Internships at **University of Otago/New Zealand** (Dunedin Public Hospital; Endocrinology and Geriatrics); **University College London/GB**, Middlesex Hospital (Endocrinology, AIDS, Cardiology) and **University Hospital Zurich/Switzerland** (Gynaecology and Obstetrics)

## Academic Certifications

2017 **Subspecialisation Title "Gynecological Oncologist"**, SIWF/ISFM Berne/ Switzerland

2015 **Full Professorship for Gynecology**, University of Basel, Switzerland

2012 **Tenure Track Ass. Professorship** for Gynaecology, University of Basel, Switzerland

2011 **FRANZCOG** Fellow of the Australian and New Zealand College of Obstetrics and Gynaecology (RANZCOG) (renewal until 2020)

2010 **CORT(GO)** Certificate of Training in Gynaecological Oncology, Australian and New Zealand College of Obstetrics and Gynaecology (RANZCOG)

2008 Conjoint **Senior Lecturer** for Gynaecology and Obstetrics, Prince of Wales Clinical School, University of New South Wales

2007 **Privatdozent (Senior Lecturer)** for Gynaecology and Obstetrics, University of Zurich/Switzerland

2007 **FMH**, Specialist for Gynaecology and Obstetrics and Operative Gynecology, Swiss Medical Foundation (Federatio Medicorum Helveticorum), Bern/Switzerland

1997 **MD**, Eberhard-Karls-University of Tübingen, Germany. **Doctoral thesis** "*Walter Edwin Griesbach (1888-1968). Live and work*", Institute of History of Medicine, University of Tübingen, Prof. D. Goltz; (magna cum laude)

## Professional Experience

01.09.2013 - **Head of the Gynecological Cancer Center**, University Hospital Basel, Switzerland

01.07.2013 - **Chair of the Women's Hospital Basel and of the Department of Gynecology and Gyn. Oncology**, University Hospital Basel, Switzerland

01.07.2012 - **Group Leader** Ovarian Cancer Group, University Hospital Basel, Department of Biomedicine

01.07.2012 - 01.07.2015 **Tenure Track Ass. Professor**, University Hospital Basel, Department of Gynaecology

01.01.2012 – 30.06.2012 RANZCOG recognized **Gynaecological Oncology Fellow**, Gynaecological Cancer Centre, Royal Adelaide Hospital, Adelaide/Australia (Prof. M. Oehler)

01.11.2009 – 30.06.2012 **Cancer Institute NSW Fellow** and **Team Leader**, Gynaecological Cancer Research Group, Lowy Cancer Research Centre, University of New South Wales, Sydney/Australia

01.01.2008 - 31.12.2010 RANZCOG recognized **Gynaecological Oncology Fellow**, Gynaecological Cancer Centre, Royal Hospital for Women, Sydney/Australia (Prof. N. Hacker, Prof. D. Marsden, Prof. M. Friedlander)

01.01.2006 – 31.12.2007 50% **Consultant** Hospital "Spital Limmattal", Zurich (R. Müller MD) and 50% **Research Group Leader** Translational Research Group, Research Department of Gynaecology, University Hospital Zurich/Switzerland (Prof. D. Fink)

01.09.2004 – 31.12.2005 **Senior Registrar** in Gynaecology and Obstetrics (Prof. D. Fink/R. Zimmermann), University Hospital Zurich

01.09.2002 – 30.08.2004 **Research Fellow** at the Garvan Institute of Medical Research, Cancer Research Program (Prof. R. Sutherland) in collaboration with the Gynaecological Cancer Centre, Royal Hospital for Women (Prof. N. Hacker), University of New South Wales, Sydney/Australia

01.07.1999 – 30.08.2002 **Resident/Registrar** in Gynaecology and Obstetrics (Prof. U. Haller/A. Huch), University Hospital Zurich

**Research Fellow** at the Research Department of Gynaecology, Drug Resistance Laboratory, University Hospital Zurich/Switzerland (D. Fink MD)

01.01.1998 – 30.06.1999 **Research Fellow** at the Research Department of Gynaecology, University Hospital Zurich/Switzerland (Prof. H. Walt/U. Haller)

## Teaching Activity

- 2015 - **Full Professor**, Coordinaton of Master Course in Reproduction; OSCE Examinations, Student Courses
- 2012 -2015 Tenure Track **Assistant Professor**, University of Basel; OSCE Examination, Teaching of Medical Students and Junior/Senior House Officers
- 2009 - 2012 **Senior Lecturer**, School of Women's and Children's Health, University of New South Wales, Sydney/Australia: Student Courses and Research
- 2008 - 2012 Privatdozentin (**Senior Lecturer**), University of Zurich: Student Courses in Gynaecology and Obstetrics
- 2006 - 2007 **Lecturer**, University of Zurich: Student Courses in Gynaecology and Obstetrics
- 1998 - 2001 **Lecturer** in Gynaecology and Obstetrics for Nurses, Nurse's Training Schools of the Red Cross Hospital and the Children's Hospital Zurich/Switzerland

## PhD and MD Theses

- Shahidul Alam (PhD Thesis, University of Basel, Switzerland) (2013-2017)
- Imad Ben Hmida (Master Thesis, Lowy Cancer Centre, UNSW) (2011-2013)
- Gaya Punnia-Moorthy (Master Thesis, Lowy Cancer Centre, UNSW) (2011-2013)
- Brian Gloss (PhD Thesis, Garvan Institute, UNSW) (2008-2011)
- Francis Jacob (PhD Thesis, University of Zurich) (2006-2010)
- Mara Meier (MD Thesis, University of Zurich) (2006-2011)
- Kristjan Ukegjini (MD Thesis, University of Zurich) (2006-2010)
- Michelle Buehler (MD Thesis, University of Zurich) (2007-2010)

## Memberships

Society of Pelvic Surgeons (SPS); Australian Medical Association (AMA); International Gynecologic Oncology Society (IGCS); Australian Society of Medical Research (ASMR); American Association for Cancer Research (AACR); AACR-Women in Cancer Research (WICR); Swiss Society of Gynaecology and Obstetrics (SGGG); Swiss Medical Association (FMH); German Society of Gynaecology and Obstetrics (DGGG), American Society of Clinical Oncology (ASCO), The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), The European Society of Contraception and Reproductive Health (ESC), European Society of Gynaecological Oncology (ESGO), Arbeitsgemeinschaft für Gynäkologische Endokrinologie und Reproduktionsmedizin, (AGER), Arbeitsgemeinschaft Gynäkologische Endoskopie (AGE), RoboGyn, TraFo der Arbeitsgemeinschaft Gynäkologische Onkologie AGO, Arbeitsgemeinschaft für Gynäkologische Onkologie und Brustgesundheit der SGGG (AGO)

## **Committees**

- 2018- Non-executive Director of the Board of Directors University Hospital Freiburg/Germany
- 2018- Editor in Chief EGONE (online learning portal SGGG)
- 2017- President Working Group Gyn Cancer SAKK (Swiss Group for Clinical Cancer Research)
- 2017- Ovarian Cancer Advisory Board (Tesarro)
- 2017- Ovarian Cancer Advisory Board (Astra Zeneca)
- 2016- Member AGO Germany (Working Group Gyn. Oncology of the German Society of Gynecology and Obstetrics)
- 2015- Board Member Swiss AGO (Working Group Gyn. Oncology of the Swiss Society of Gynecology and Obstetrics)
- 2015- Member of the Scientific Committee Research Foundation University Foundation Basel
- 2014- Member of the Working Groups SwissEndos (Laparoscopic Surgery) and RoboGyn (Robotic Surgery) of the Swiss Society of Gynecology and Obstetrics
- 2014-2017 Committee Member EGONE (Online Learning Platform of the Swiss Society of Gynecology and Obstetrics)
- 2014-2016 Board Member Ethics Committee University Hospital Basel
- 2013- Ovarian Cancer Advisory Board (Amgen)
- 2013- TachoSil Expert Board
- 2012- Swiss Ovarian Cancer Advisory Board (Roche)
- 2008 - 2012 Scientific Review Committee of the Human Research Ethics Committee of the Northern Hospital Network, Prince of Wales Hospital, Randwick, Australia
- 2006 - 2011 PhD Thesis Committee, Cancer Network Zurich, University of Zurich, Switzerland

## **Scientific Reviewer**

### **Journals**

PLoS ONE, Biomarkers in Medicine, Journal of Cancer Research and Clinical Oncology, International Journal of Gynaecological Oncology, Asia-Pacific Journal of Medical Oncology, British Journal of Cancer, Tumor Biology, The Australian and New Zealand Journal of Obstetrics and Gynaecology, Cancer Biomarkers, International Journal of Molecular Biology, Oncotarget

### **Funding Organisations**

Swiss National Foundation (CH), Oncosuisse (CH), NHMRC (AUS)

### **Conferences**

SGGG, DGGG, TOW Poster Session, UNSW

## Editorships

BioMed Research International (editor); Journal of Gynecologic and Obstetric Investigation (associate editor)

## Awards

- 2007 **European Science Foundation**, Travel Award 'Frontiers in Functional Genomics', Strasbourg/France (**6'700 SFr**)
- 2006 **SIAK/Pfizer Award** from the Swiss Institute of Applied Cancer Research, Mid-Term Meeting Basel/Switzerland (**20'000 SFr**)
- 2005 Poster Award, Annual Meeting of the Swiss Society for Gynaecologists and Obstetricians (SGGG), Lugano/Switzerland
- 2004 **SGGG-Prize** 2004 from the Swiss Society for Gynaecologists and Obstetricians, Annual Meeting of the SGGG, Interlaken/Switzerland (**20'000 SFr**)
- 2003 Poster Prize, Annual Meeting of the Swiss Society for Gynaecologists and Obstetricians (SGGG), Lugano/Switzerland
- 2003 Poster Award, 29th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology Limited, Sydney/Australia
- 2003 Travel Award, Australian Society for Medical Research, 42<sup>nd</sup> National Scientific Conference, Adelaide/Australia
- 1998 **Henry-E.-Sigerist Award** (Dr. Markus Guggenheim-Schnurr-Foundation), Swiss Association for History of Medicine for the doctoral thesis "Walter Edwin Griesbach (1888-1969). Live and work" (**2'000 SFr**). Luzern/Switzerland.

## Research Funding (total 4.74 Mio SFR/AUD)

- 2016 Swiss National Science Foundation (SNF), Synergia Grant: 48 Months, *1'987'700 SFr*
- 2014 Swiss National Science Foundation (SNF), Research Project Grant: 12 Months; *128'000 SFr*
- 2013 Nora van Meeuwen-Häfliger Stiftung: 24 Months in Ergänzung zum Oncosuisse Grant; *25'000 SFr*
- 2013 Cancer League Basel: 6 Months; *30'000 SFr*
- 2013 Ovarian Cancer Research Foundation Australia: 24 Months; *\$ 139'113 (CID on Grant Caroline Ford)*
- 2012 Cancer Council SA/ NHMRC Australia: 12 Months; *\$ 90'000 (CIC on Grant C Ricciardelli)*
- 2012 Swiss National Science Foundation (SNF), Research Project Grant: 24 Months; *245'000 SFr*
- 2012 Oncosuisse, Research Project Grant: 36 Months; *200'000 SFr*
- 2012 GO Research Fund / Royal Hospital for Women Foundation: 6 Months *\$ 60'000*
- 2011 Cure Cancer Grant / NHMRC: 12 Months; *\$ 90'000 (CIB Grant CE Ford)*

- 2010 Swiss National Science Foundation (SNF), Research Scholarship for PhD Student F. Jacob: 12 Months; *89'000 SFr*
- 2009 Mary Elizabeth Courier Research Scholarship (RANZCOG): 36 Months; *\$ 90'000*
- 2009 Clinical Research Fellowship Grant Cancer Institute NSW: 36 Months; *\$ 695'500*
- 2009 William Maxwell Trust: 36 Months; *\$ 120'000*
- 2008 Swiss National Science Foundation (SNF), Research Project Grant: 36 Months; *243'000 SFr*
- 2007 Oncosuisse, Research Project Grant: 24 Months; *230'000 SFr*
- 2006 Cancer League Zurich, Research Project Grant: 36 Months; *167'000 SFr*
- 2002 Swiss Academy of Medical Sciences (SAMW/Swiss National Science Foundation (SNF)) 2002, Research Scholarship: 24 Months; *119'480 SFr*
- 2002 Scientific Fund of the Clinic of Gynaecology, University Hospital Zurich, Research Scholarship: 24 Months; *10'000 SFr*

### **Didactical/Management Qualifications**

- 2017 CAS Leadership Refresher (Refresher, University of Berne/Switzerland)
- 2016 Investigator Site Personnel GCP Training (Pfizer)
- 2014 CAS Leadership (College M, University of Berne/Switzerland)
- 2013 Clinical Trial Unit Course for Sponsor-Investigators (University Basel/Switzerland)
- 2013 Examiner-Training into OSCE (objective structured clinical examination) (University Basel/Switzerland)
- 2012 Clinical Trial Unit Course GCP for Investigators/Study Managers (University Basel/Switzerland)
- 2011 Intellectual Property and Commercialisation (UNSW, Sydney/Australia)
- 2011 Negotiating and Conflict Management (UNSW, Sydney/Australia)
- 2011 Develop your Voice (UNSW, Sydney/Australia)
- 2011 Strategic Thinking and Operational Planning (UNSW, Sydney/Australia)
- 2011 Chairing Meetings (UNSW, Sydney/Australia)
- 2007 Strategies for negotiations and conflicts, PRO-WISS (Equality Mentoring Program), University Zurich/Switzerland
- 2006 Project and Time Management, PRO-WISS (Equality Mentoring Program), University Zurich/Switzerland
- 2006 Networking, PRO-WISS (Equality Mentoring Program), University Zurich/Switzerland
- 2005 University Didactical Methods for Associate Professors, University Zurich/Switzerland
- 2005 Non-violent Communication Skills (by Marshall B. Rosenberg), PRO-WISS (Equality Mentoring Program), University Zurich/Switzerland
- 2005 Grant Acquisition, PRO-WISS (Equality Mentoring Program), University Zurich/Switzerland

## **Participation at International Meetings**

ESGO Biennial International Meeting, Wien/Austria, **03. - 05.11.2017**

GCIG Gynecologic Cancer Intergroup, Wien/Austria, **02.11.2017**

ENGOT Meeting, Frankfurt/Deutschland, **13.10.2017**

ENGOT – Rare cancer meeting, Frankfurt/Deutschland, **25.09.2017**

Speaker at 11th Swiss Post ASCO, Bern/Switzerland, **22.06.2017**

ASCO American Society of Clinical Oncology, Chicago/USA, **02. – 06.06.2017**

Invited Speaker at XXVI. Scientific Meeting of the Austrian AGO Salzburg/Austria, **26. – 28.04.2017**

15th St. Gallen International Breast Cancer Conference, Wien/Austria, **15. – 17.03.2017**

ENGOT Meeting, European Network of Gynaecological Oncology Trial Groups  
Prague, Czech Republic, **04.03.2017**

IGCS 16th Biennial Meeting of the International Gynecologic Cancer Society, Lisboa/Portugal,  
**29.10.-31.10.2016**

66th Annual Meeting of the Society of Pelvic Surgeons, St. Louis/USA, **04.10.-08.10.2016**

ASCO American Society of Clinical Oncology, Chicago/USA, **03.06.-07.06.2016**

The European Congress and Council Meeting EBCOG, Torino/Italy, **18.05.2016**

ESC Congress Basel/Switzerland, **06.05.2016** (Chair)

Invited Speaker, The fourth annual Health-Science Alliance symposium, Randwick/Australia,  
**16.11.-21.11.2015**

ESGO19 International Meeting of the European Society of Gynaecological Oncology,  
Nizza/France, **24.10.-27.10.2015**

65th Meeting of the Society of Pelvic Surgeons, San Francisco/USA, **20.10.-23.10.2015**

XXIV. Academic Meeting of German Speaking Chiars in Gynecology and Obstetrics,  
Warth/Switzerland, **25.09.-26.09.2015**

ASCO American Society of Clinical Oncology, Chicago/USA, **29.05.-02.06.2015**

Da Vinci GYN advanced course, Wendisch-Rietz/Germany, **13.05.2015**

14th St. Gallen International Breast Cancer Conference, Wien/Austria, **17.03.-21.03.2015**

Progress and Controversies in Gynecologic Oncology Conference, Barcelona/Spain, **16.01.-  
17.01.2015**

10th Biennial Ovarian Cancer Research Symposium, Seattle/USA, **07.09.-10.09.2014**

Member Working Group SIWF/FMH „Charta for the Collaboration of various Health Care Professionals“, Bern/Switzerland, **26.08.2014**

Invited Speaker 8th Swiss Post ASCO, Bern/Switzerland, **12.06.2014**

ASCO American Society of Clinical Oncology, Annual Meeting, Chicago/USA, **30.05.-03.06.2014**

21<sup>st</sup> Annual Meeting of the Eucc European Cancer Center, Basel/Switzerland, **16.05.2014**

ESGO 18<sup>th</sup> International Meeting of the European Society of Gynaecological Oncology, Liverpool/England, **19.-22.10.2013**

Invited Speaker SAMO Interdisciplinary Workshop on Gynecologic Tumors, Luzern/Switzerland, **04.-05.10.2013**

13<sup>th</sup> St. Gallen International Breast Cancer Conference 2013, St. Gallen/ Switzerland, **13.-16.03.2013**

Biannual Meeting of the German Society of Gynaecologists and Obstetricians, Munich, Germany, **09.-13.10.2012**

Invited Speaker, First Cervical Cytology Symposium. Cervical cytology – a success model. Pfäffikon/Switzerland, **06.09.2012**

Advanced Gynaecological Laparoscopy Course, Sydney Women’s Endoscopic Centre, St. George Hospital, Sydney/Australia, **10.-14.10.2011**

Annual Meeting of the Australian Society of Gynaecologic Oncology, Margaret River/Australia, **24.-28.04.2010**

Anatomy of Complications Workshop Gynaecological Oncology (Prof. Ian Hammond), Perth/Australia, **22.-23.04.2010**

Annual Meeting of the Australian Society of Gynaecologic Oncology, Noosa, **01.-05.04.2009**

Anatomy of Complications Workshop Gynaecology (Prof. Ian Hammond), Perth, **06.-07.02.2009**

Annual Meeting of the Australian Society of Gynaecologic Oncology (Fellow’s Talk), Hobart, **01.-05.04.2008**

Annual Meeting of the Australian Society of Gynaecologic Oncology (Fellow’s Talk), Singapore, **12.-16.05.2004**

Annual Meetings of the Swiss Society of Gynaecologists and Obstetricians, 1998-2002, 2005-2007

## **Scientific Performance**

h-index: 24 (39 last 5 years)

Citations: 2229 (1317 last 5 years)



## Publication List

### (A) Peer-reviewed Publications

65. Dueckelmann AM, Fink D, Harter P, **Heinzelmann V**, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology. **Arch Gynecol Obstet.** (2018). doi: 10.1007/s00404-018-4673-0. [Epub ahead of print] Review.
64. **Heinzelmann-Schwarz V**, Knipprath Mészáros A, Stadlmann S, Jacob F, Schoetzau A, Russell K, Friedlander M, Singer G, Vetter M. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. **Gynecol Oncol** 148(1):79-85 (2018)
63. Magaton IM, Tzankov A, Krasniqi F, Rottenburger C, Zanetti-Daellenbach R, Grendelmeier P, **Heinzelmann-Schwarz V**, Mayr M, Schwab FD. Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study. **Case Rep Oncol.** Oct 5;10(3):876-884. (2017)
62. Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bühner-Landolt R, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinemann K, **Heinzelmann-Schwarz V**, Pagani O, Chappuis PO. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. **JMIR Res Protoc.**6(9):e184. (2017)
61. Anugraham M, Jacob F, Everest-Dass AV, Schoetzau A, Nixdorf S, Hacker NF, Fink D, Heinzelmann-Schwarz V, Packer NH. Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma. **Mol Oncol.** doi: 10.1002/1878-0261.12134. (2017)
60. Pochechueva T, Alam S, Schötzau A, Chinarev A, Bovin NV, Hacker NF, Jacob F, **Heinzelmann-Schwarz V**. Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. **J Ovarian Res.** 2017;10:8. (2017)
59. Kohler RS, Kettelhack H, Knipprath-Mészáros AM, Fedier A, Schötzau A, Jacob F, **Heinzelmann-Schwarz V**. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. **Gynecol Oncol.** 145:159-166. (2017)
58. Pochechueva T, Chinarev A, Schoetzau A, Fedier A, Bovin NV, Hacker NF, Jacob F, **Heinzelmann-Schwarz V**. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients. **PLoS One.** 2016 Oct 20;11(10):e0164230. doi:10.1371/journal.pone.0164230.
57. Katsara A, Wight E, **Heinzelmann V**, Kavvadias T, Long term quality of life, satisfaction, pelvic floor symptoms and regret after colpocleisis. (2016). **Archives of Obstetrics and Gynecology** accepted
56. Kohler RS, Anugraham M, Nunez Lopez M, Xiao C, Schoetzau A, Hettich T, Schlotterbeck G, Fedier A, Jacob F, **Heinzelmann-Schwarz VA**, Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients. (2016). **Oncotarget** accepted
55. Manegold-Brauer G, Buechel J, Knipprath-Mészáros A, Schoetzau A, Hacker NF, Tercanli S, Lapaire O, **Heinzelmann-Schwarz V**. Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting. **Int J Gynecol Cancer.** 2016 Jul;26(6):1062-9. doi: 10.1097/IGC.0000000000000718. PMID: 27177281

54. Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, **Heinzelmann-Schwarz VA**, Umana P, Pisa P, Lardinois D, Müller P, Karanikas V, Zippelius A. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. *Oncoimmunology*. 2015 Jun 24;5(2):e1062969. eCollection 2016 Feb. PMID: 27057429
53. Manegold-Brauer G, Buechel J, Knipprath-Mészáros A, Schoetzau A, Hacker NF, Tercanli S, Lapaire O, **Heinzelmann-Schwarz V**. Improved detection rate of ovarian cancer using a two-step triage model of the Risk of Malignancy Index (RMI) and expert sonography in an outpatient screening setting. *International Journal of Gynecological Cancer* (02/2016)
52. Henry C, Llamosas E, Knipprath-Mészáros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, **Heinzelmann-Schwarz V**, Ford C. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. *Oncotarget*. 2015 Nov 24;6(37):40310-26. doi: 10.18632/oncotarget.5643.
51. Henri C, Llamosas E, Knipprath-Mészáros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, **Heinzelmann-Schwarz V**, Ford C. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. *Oncotarget* (2015) Nov 24;6(37):40310-26.
50. Decollogne S, Joshi S, Chung SA, Luk PP, Yeo RX, Nixdorf S, Fedier A, **Heinzelmann-Schwarz V**, Hogg PJ, Dilda PJ. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. *Gynecol Oncol*. Gynecol Oncol. (2015) Aug;138(2):363-71.
49. Manegold-Brauer G, **Heinzelmann-Schwarz V**. Comment on the letter: The mass cannot be classified as malignant. *Arch Gynecol Obstet* (2015) Mar;291(3):475.
48. Sartorius G, Montavon C, Vetter M, **Heinzelmann-Schwarz V** (2014). Hormonsubstitution nach Ovarialkarzinomen und Borderline-Tumoren des Ovars. *Frauenheilkunde up2date* 4. (2014).
47. Manegold-Brauer G, Heinzelmann-Schwarz V. Comment on the Letter: The mass cannot be classified as malignant. *Arch Gynecol Obstet*. [Epub ahead of print]. (2014). (IF=1.3)
46. Jacob F, Hitchins MP, Fedier A, Brennan K, Nixdorf S, Hacker NF, Ward R, **Heinzelmann-Schwarz V**. Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells. *BMC Mol Biol*. 15:24. DOI: 10.1186/1471-2199-15-24. (2014). (IF=2.1)
45. Jacob F, Anugraham M, Pochechueva T, Tse B, Alam S, Guertler R, Bovin NV, Fedier A, Hacker NF, Huflejt ME, Packer N, **Heinzelmann-Schwarz VA**. The glycosphingolipid P1 is an ovarian cancer-associated carbohydrate antigen involved in migration. *Brit J Cancer* 111:1634-1645. (2014). (IF=4.8)
44. Pochechueva T, Chinarev A, Bovin N, Fedier A, Jacob F, **Heinzelmann-Schwarz V**. PEGylation of microbead surfaces reduces unspecific antibody binding in glycan-based suspension array. *J Immunol Methods* 412:42-52 (2014). (IF=2.0)
43. Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, **Heinzelmann-Schwarz VA**, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhöfer St, Speiser DE, von Bergwelt-Baildon M, Zippelius A. Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. *Cancer Immunol Res* 2:741-755. (2014).

42. Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, **Heinzelmann-Schwarz VA**, Thommen DS, Zippelius A. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. *Cancer Immunol Immunother* 63:925-938. (2014). (IF=3.9)
41. Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J, Caduff R, Ward RL, **Viola Heinzelmann-Schwarz**, Ford CE. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. *Gynecol Oncol* 134:338-345. (2014). (IF=3.7)
40. Jacob F, Anugraham M, Nixdorf S, Everest-Dass AV, **Heinzelmann-Schwarz VA**, Packer NH. Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status. *Mol Cell Proteomics* 13:2213-2232. (2014). (IF=7.3)
39. Jacob F, Nixdorf S, Hacker NF, **Heinzelmann-Schwarz VA**. Reliable in vitro studies require appropriate ovarian cancer cell lines. *J Ovarian Res* 7:60. (2014). IF=2.0)
38. **Heinzelmann-Schwarz V**, Kind AB, Jacob F. Management of human papillomavirus-related gynecological malignancies. *Curr Probl Dermatol*. 45:216-24. (2014).
37. **Heinzelmann-Schwarz VA**, Nixdorf S, Valadan M, Diczbalis M, Olivier J, Otton G, Fedier A, Hacker NF, Scurry JP. A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker. *Int J Mol Med* 33:784-794. (2014). (IF=1.9)
36. Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, **Heinzelmann-Schwarz V**. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors and distinction from other methods of diagnostic imaging. *Arch Gynecol Obstet* 289:491-498. (2014). (IF=1.3)
35. Tse B, Collins, A, Oehler MK, Zippelius A, **Heinzelmann-Schwarz V**. Antibody based immunotherapy – where are we at? *Ann Oncol* 25:322-331. (2014). (IF=6.6)
34. Thieringer F, Sartorius G, Kalf K, **Heinzelmann V**, Vetter M. Bilateral Breast Masses with a Rare Etiology (Case Report). *Case Reports in Oncological Medicine* doi.org/10.1155/2013/412368. (2013).
33. Schwab FD, Bürki N, Huang DJ, **Heinzelmann-Schwarz V**, Schmid SM, Vetter M, Schötzu A, Güth U. Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. *Fam Cancer* 13:99-107. (2013). (IF=1.6)
32. Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D, Goldstein DR, **Heinzelmann-Schwarz V**. Meta-Analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. *Biomed Res Int* 2013;2013:238284. (2013). (IF=2.7)
31. Jacob F, Guertler, R, Naim, S, Nixdorf, S, Fedier, A, Hacker, NF, **Heinzelmann-Schwarz V**. Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines. *PLOS ONE*: 8(3):e59180. (2013). (IF=3.5)
30. Gueth U, Vetter M, Huang DJ, **Heinzelmann-Schwarz V**. Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease. *Ann Oncol* 24:555-557. (2013). (IF=6.6)

29. Ford CE, Jary E, Ma SSQ, Nixdorf S, Ward RL, **Heinzelmann-Schwarz V**. The wnt gatekeeper sFRP4 modulates EMT, cell migration and downstream wnt signaling in serous ovarian cancer cells. *PLOS ONE* 8(1):e54362. (2013). (IF=3.5)
28. Pochechueva T, Jacob F, Fedier A, **Heinzelmann-Schwarz V**. Tumor-Associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. *Metabolites* 2:913-939. (2012).
27. Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam, D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie E, AOCS, Pearson RB, Harnett PR, **Heinzelmann-Schwarz V**, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DDL. Deletion of LRP1B is associated with acquired chemotherapy resistance to liposomal doxorubicin in high-grade serous ovarian cancer. *Cancer Res* 72:4060-4073. (2012). (IF=9.9)
26. Jacob F, Ukegini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry J, Guertler R, Hornung D, Mueller R, Fink DA, Hacker NF, **Heinzelmann-Schwarz VA**. Loss of secreted frizzled-related protein 4 correlates with a more aggressive phenotype and is an independent predictor of poor outcome in ovarian cancer patients. *PLOS ONE* 7(2):e31885. (2012). (IF=3.5)
25. Jacob F, Goldstein DR, Bovin NV, Pochechueva T, Spengler M, Caduff R, Fink D, Vuskovic MI, Huflejt ME, **Heinzelmann-Schwarz V**. Serum anti-glycan antibody detection of non-mucinous ovarian cancers by using a printed glycan array. *Int J Cancer* 130:138-146. (2012). (IF=5.0)
24. Chang CY, Picotti P, Huettenhain R, **Heinzelmann-Schwarz V**, Iovanovic M, Aebersold R, Vitek O. Statistical framework for protein quantification with Selected Reaction Monitoring (SRM) experiments. *Mol Cell Proteomics* 11:M111.014662. (2011). (IF=7.3)
23. Pochechueva T, Jacob F, Goldstein DR, Huflejt ME, Chinarev, A, Caduff R, Fink D, Hacker N, Bovin NV, **Heinzelmann-Schwarz V**. Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies. *Glycoconj J* 28:507-517. (2011). (IF=2.0)
22. **Heinzelmann-Schwarz V**. Epithelial ovarian cancer – a change of paradigm. Invited review. *Ther Umsch* 68:565-572. (2011).
21. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, **Heinzelmann-Schwarz V**. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. *Gynaecol Oncol* 121:487-91. (2011). (IF=3.7)
20. Theurillat JP, Metzler S, Henzi N, Djouder N, Helbling M, Zimmermann AK, Jacob F, Soltermann A, Caduff R, **Heinzelmann-Schwarz V**, Moch H, Krek W. URI Is an Oncogene Amplified in Ovarian Cancer Cells and Required for Their Survival. *Cancer Cell* 19:317-332. (2011). (IF=23.9)
19. Pochechueva T, Chinarev A, Spengler M, Korchagina E, **Heinzelmann-Schwarz V**, Bovin N, Rieben R. Multiplex suspension array for human anti-carbohydrate antibody profiling. *Analyst* 136:560-569. (2011). (IF=3.9)
18. Jacob F, Goldstein D, Fink D, **Heinzelmann-Schwarz V**. Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs. *Biomarkers Med* 3 :743-746. (2009). (IF=2.9)
17. O'Brien P M, Davies M J, Scurry J P, Smith A N, Barton, C A, Henderson M J, Saunders D N, Clancy J L, **Heinzelmann-Schwarz V A**, Scolyer R A, Zeng, Y, Williams E D, Scurry L, DeFazio A, Quinn D I, Watts C K W, Hacker N F, Henshall S M, Sutherland R L. The E3 ubiquitin

ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. *Br J Cancer* 98:1085-1093. (2008). (IF=4.8)

16. **Heinzelmann-Schwarz VA**, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, VandenBergh P, Baron-Hay S, Scott C, Ward RL, Morey A, Fink D, Hacker NF, Sutherland RL, O'Brien PM. High galectin 4 and low meprin alpha expression differentiates primary mucinous epithelial ovarian carcinoma from mucinous gastrointestinal cancers. *J Clin Path* 60:622-626. (2007). (IF=2.6)

15. **Heinzelmann-Schwarz VA**, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, VandenBergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM. A distinct molecular profile associated with mucinous epithelial ovarian cancer. *Br J Cancer* 94:904-913. (2006). (IF=4.8)

14. **Heinzelmann-Schwarz V**, Gardiner-Garden M, Henshall S, Scurry J, Scolyer R, Davies M, Heinzelmann M, Kalish L, Bali A, Kench J, VandenBergh P, Hacker N, Sutherland RL, O'Brien P. Overexpression of the cell adhesion molecules DDR1, claudin 3 and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. *Clin Cancer Res* 10:4427-4436. (2004). (IF=8.2)

13. Degen AF, Gabrecht T, Mosimann L, Fehr MK, Hornung R, **Schwarz VA**, Tadir Y, Steiner RA, Wagnieres G, Wyss P. Photodynamic endometrial ablation for the treatment of dysfunctional uterine bleeding: a preliminary report. *Lasers Surg Med* 34:1-4. (2004). (IF=2.6)

12. **Heinzelmann-Schwarz V**, Fedier A, Hornung R, Walt H, Haller U, Fink D. The role of p53 and ATM in photodynamic therapy-induced apoptosis. *Lasers Surg Med* 33:182-189. (2003). (IF=2.6)

11. Fedier A, Schlamming M, **Schwarz VA**, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. *Ann Oncol* 14:938-945. (2003). (IF=6.6)

10. Wyss P, Caduff R, Tadir Y, Degen A, Wagnieres G, **Schwarz V**, Haller U, Fehr M. Photodynamic endometrial ablation: Morphological study. *Lasers Surg Med* 32:305-309. (2003). (IF=2.6)

9. Fedier A, Steiner RA, **Schwarz VA**, Lenherr L, Haller U, Fink D. The effect of loss of Brca 1 on the sensitivity to anticancer agents in p53-deficient cells. *Int J Oncol* 22:1169-1173. (2003). (IF=2.8)

8. Fedier A, Ruefenacht UB, **Schwarz VA**, Haller U, Fink D. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of PMS2. *Br J Cancer* 87:1027-1033. (2002). (IF=4.8)

7. Fehr M, Hornung R, Degen A, **Schwarz VA**, Fink D, Haller U, Wyss P. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. *Lasers Surg Med*. 30:273-279. (2002). (IF=2.6)

6. **Schwarz VA**, Hornung R, Fedier A, Walt H, Haller U, Fink D. Photodynamic therapy in DNA mismatch repair -deficient and -proficient tumors. *Br J Cancer* 86:1130-1135. (2002). (IF=4.8)

5. Fedier A, **Schwarz VA**, Walt H, Carpini RD, Haller U, Fink D. Resistance To Topoisomerase Inhibitors Due To Loss Of DNA Mismatch Repair. *Int J Cancer* 93:571-576. (2001). (IF=5.0)

4. Fehr MK, Hornung R, **Schwarz VA**, Simeon R, Haller U, Wyss P. Photodynamic Therapy of Vulvar Intraepithelial Neoplasia III Using Topically Applied 5-Aminolevulinic Acid. *Gynecol Oncol* 80:62-66. (2001). (IF=3.7)

3. Wyss P, **Schwarz V**, Dobler-Girdziunaite D, Hornung R, Haller U, Degen A, Fehr M. Photodynamic Therapy of Locoregional Breast Cancer Recurrences using a Chlorin-type Photosensitizer. *Int J Cancer* 93:720-724. (2001). (IF=5.0)
2. **Schwarz VA**, Klein SD, Knochenmuss R, Hornung R, Haller U, Wyss P, Fink D, Walt H. Topical skin protection for photosensitized patients. *Lasers Surg Med* 29:252-259. (2001). (IF=2.6)
1. **Schwarz VA**. In memory of the pharmacologist, metabolic pathologist and endocrinologist Walter Edwin Griesbach (1888-1968). *Dtsch Med Wochenschr* 124:A22-A24. (1999).

## **(B) AOCS papers as a member of the AOCS Study Group**

Milne RL, Lorenzo-Bermejo J, Burwinkel B, Malats N, Arias JI, Zamora MP, Benítez J, Humphreys MK, García-Closas M, Chanock SJ, Lissowska J, Sherman ME, Mannermaa A, Kataja V, Kosma VM, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Anton-Culver H, Ziogas A, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Liu J, Irwanto AK, Kang D, Yoo KY, Noh DY, Couch FJ, Olson JE, Wang X, Fredericksen Z, Nordestgaard BG, Bojesen SE, Flyger H, Margolin S, Lindblom A, Fasching PA, Schulz-Wendtland R, Ekici AB, Beckmann MW, Wang-Gohrke S, Shen CY, Yu JC, Hsu HM, Wu PE, Giles GG, Severi G, Baglietto L, English DR, Cox A, Brock I, Elliott G, Reed MW, Beesley J, Chen X, Investigators K; **Australian Ovarian Cancer Study Group\***, Fletcher O, Gibson L, dos Santos Silva I, Peto J, Frank B, Heil J, Meindl A, Chang-Claude J, Hein R, Vrieling A, Flesch-Janys D, Southey MC, Smith L, Apicella C, Hopper JL, Dunning AM, Pooley KA, Pharoah PD, Hamann U, Pesch B, Ko YD; GENICA Network, Easton DF, Chenevix-Trench G. 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. *J Med Genet.* 48:698-702. (2011). (IF=4.6)

Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Arias Pérez JI, Benítez J, Dörk T, Schürmann P, Karstens JH, Hillemanns P, Cox A, Brock IW, Elliot G, Cross SS, Seal S, Turnbull C, Renwick A, Rahman N, Shen CY, Yu JC, Huang CS, Hou MF, Nordestgaard BG, Bojesen SE, Lanng C, Grenaker Alnæs G, Kristensen V, Børresen-Dale AL, Hopper JL, Dite GS, Apicella C, Southey MC, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Chang-Claude J, Wang-Gohrke S, Radice P, Peterlongo P, Manoukian S, Barile M, Giles GG, Baglietto L, John EM, Miron A, Chanock SJ, Lissowska J, Sherman ME, Figueroa JD, Bogdanova NV, Antonenkova NN, Zalutsky IV, Rogov YI, Fasching PA, Bayer CM, Ekici AB, Beckmann MW, Brenner H, Müller H, Arndt V, Stegmaier C, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Meindl A, Heil J, Bartram CR, Schmutzler RK, Thomas GD, Hoover RN, Fletcher O, Gibson LJ, dos Santos Silva I, Peto J, Nickels S, Flesch-Janys D, Anton-Culver H, Ziogas A, Sawyer E, Tomlinson I, Kerin M, Miller N, Schmidt MK, Broeks A, Van 't Veer LJ, Tollenaar RA, Pharoah PD, Dunning AM, Pooley KA, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Jakubowska A, Lubinski J, Jaworska K, Durda K, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Kraft P, Lindstrom S, Chen X, Beesley J, Hamann U, Harth V, Justenhoven C; GENICA Network, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Hooning M, Hollestelle A, Oldenburg RA, Tilanus-Linthorst M, Khusnutdinova E, Bermisheva M, Prokofieva D, Farahtdinova A, Olson JE, Wang X, Humphreys MK, Wang Q, Chenevix-Trench G; kConFab Investigators; **Australian Ovarian Cancer Study Group**, Easton DF. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiol Biomarkers Prev.* 20:2222-2231. (2011). (IF=4.3)

Beesley VL, Price MA, Butow PN, Green AC, Olsen CM; **Australian Ovarian Cancer Study Group**; Australian Ovarian Cancer Study - Quality of Life Study Investigators, Webb PM.

Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. *Psychooncology*. 20:1161-1169. (2011).

Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell P, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall EV, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi KO, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Dolan ME, **Australian Ovarian Cancer Study Group**. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. *Clin Cancer Res*. 17:5490-5500. (2011). (IF=8.2)

Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Van 't Veer LJ, de Groot R, Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Orsted DD, Kaur-Knudsen D, Milne RL, Pérez JI, Zamora P, Rodríguez PM, Benítez J, Brauch H, Justenhoven C, Ko YD; The Genica Network, Hamann U, Fischer HP, Brüning T, Pesch B, Chang-Claude J, Wang-Gohrke S, Bremer M, Karstens JH, Hillemanns P, Dörk T, Nevanlinna HA, Heikkinen T, Heikkilä P, Blomqvist C, Aittomäki K, Aaltonen K, Lindblom A, Margolin S, Mannerma A, Kosma VM, Kauppinen JM, Kataja V, Auvinen P, Eskelinen M, Soini Y, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Holland H; kConFab; **Australian Ovarian Cancer Study Group**, Lambrechts D, Claes B, Vandrope T, Neven P, Wildiers H, Flesch-Janys D, Hein R, Löning T, Kosel M, Fredericksen ZS, Wang X, Giles GG, Baglietto L, Severi G, McLean C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Grenaker Alnæs G, Kristensen V, Børresen-Dale AL, Hunter DJ, Hankinson SE, Andrulis IL, Marie Mulligan A, O'Malley FP, Devilee P, Huijts PE, Tollenaar RA, Van Asperen CJ, Seynaeve CS, Chanock SJ, Lissowska J, Brinton L, Peplonska B, Figueroa J, Yang XR, Hooning MJ, Hollestelle A, Oldenburg RA, Jager A, Kriege M, Ozturk B, van Leenders GJ, Hall P, Czene K, Humphreys K, Liu J, Cox A, Connley D, Cramp HE, Cross SS, Balasubramanian SP, Reed MW, Dunning AM, Easton DF, Humphreys MK, Caldas C, Blows F, Driver K, Provenzano E, Lubinski J, Jakubowska A, Huzarski T, Byrski T, Cybulski C, Gorski B, Gronwald J, Brennan P, Sangrajrang S, Gaborieau V, Shen CY, Hsiung CN, Yu JC, Chen ST, Hsu GC, Hou MF, Huang CS, Anton-Culver H, Ziogas A, Pharoah PD, Garcia-Closas M. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Hum Mol Genet*. Jun 9. (2011). (IF=6.7)

Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whittmore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G; **Australian Ovarian Cancer Study Group/ACS Study Group**, Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. *Hum Mol Genet*. 20:2263-2272. (2011). (IF=6.7)

Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB; **Australian Ovarian Cancer Study Group**, Bowtell DD, Harvey KF. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. *Oncogene* 30:2810-2822. (2011). (IF=8.6)

O'Mara TA, Fahey P, Ferguson K, Marquart L, Lambrechts D, Despierre E, Vergote I, Amant F, Hall P, Liu J, Czene K; SASBAC, Rebbeck TR; WISE Study Group; **Australian Ovarian Cancer Study Group**; SEARCH, Ahmed S, Dunning AM, Gregory CS, Shah M; ANECS, Webb PM, Spurdle AB. Progesterone receptor gene variants and risk of endometrial cancer. *Carcinogenesis* 32:331-335. (2011). (IF=5.3)

Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM, Kjær SK, Hogdall E, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Schildkraut JM, Moorman PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL; Ovarian Cancer Association Consortium; Australian Cancer Study (Ovarian Cancer) (ACS); Australian Ovarian Cancer Study Group **Australian Ovarian Cancer Study Group**. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. *Fertil Steril*. 95:40-45. (2011). (IF=4.3)

Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Waltes R, Bremer M, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Humphreys K, Liu J, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G; kConFab Investigators; **Australian Ovarian Cancer Study Group**, Beesley J, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Ko YD, Hamann U; GENICA Consortium, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Milne RL, Benítez J, Arias JI, Pita G, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Margolin S, Lindblom A, Humphreys MK, Morrison J, Platte R, Easton DF, Peto J; Breast Cancer Association Consortium. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. *Cancer Epidemiol Biomarkers Prev*. 19:2143-2151. (2010). (IF=4.3)

Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benítez J, Arias Pérez JI, Zamora MP, Malats N, Dos Santos Silva I, Gibson LJ, Fletcher O, Johnson N, Anton-Culver H, Ziogas A, Figueroa J, Brinton L, Sherman ME, Lissowska J, Hopper JL, Dite GS, Apicella C, Southey MC, Sigurdson AJ, Linet MS, Schonfeld SJ, Freedman DM, Mannermaa A, Kosma VM, Kataja V, Auvinen P, Andrulis IL, Glendon G, Knight JA, Weerasooriya N, Cox A, Reed MW, Cross SS, Dunning AM, Ahmed S, Shah M, Brauch H, Ko YD, Brüning T; GENICA Network, Lambrechts D, Reumers J, Smeets A, Wang-Gohrke S, Hall P, Czene K, Liu J, Irwanto AK, Chenevix-Trench G, Holland H; kConFab; **Australian Ovarian Cancer Study Group**, Giles GG, Baglietto L, Severi G, Bojesen SE, Nordestgaard BG, Flyger H, John EM, West DW, Whittemore AS, Vachon C, Olson JE, Fredericksen Z, Kosel M, Hein R, Vrieling A, Flesch-Janys D, Heinz J, Beckmann MW, Heusinger K, Ekici AB, Haeberle L, Humphreys MK, Morrison J, Easton DF, Pharoah PD, García-Closas M, Goode EL, Chang-Claude J. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. *Breast Cancer Res*. 12:R110. (2010). (IF=5.9)

Kolahdooz F, van der Pols JC, Bain CJ, Marks GC, Hughes MC, Whiteman DC, Webb PM, **Australian Ovarian Cancer Study Group**. Meat, fish, and ovarian cancer risk: results from 2 Australian case-control studies, a systematic review, and meta-analysis. *Am J Clin Nutr*. Apr 14 (Epub). (2010). (IF=6.9)

Nagle CM, Olsen CM, Bain CJ, Whiteman DC, Green AC, Webb PM, **Australian Ovarian Cancer Study Group**. Tea consumption and risk of ovarian cancer. *Cancer Cause Control* May 20 (Epub). (2010). (IF=3.0)

Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, Chen XQ, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, Wang-Gohrke S, Hein R, Green AC, Lissowska J, Carney ME, Lurie G, Wilkens LR, Ness RB, Pearce CL,



Wu AH, Van Den Berg DJ, Stram DO, Terry KL, Whiteman DC, Whittemore AS, DiCioccio RA, McGuire V, Doherty JA, Rossing MA, Anton-Culver H, Ziogas A, Hogdall C, Hogdall E, Krüger Kjaer S, Blaakaer J, Quaye L, Ramus SJ, Jacobs I, Song H, Pharoah PD, Iversen ES, Marks JR, Pike MC, Gayther SA, Cunningham JM, Goodman MT, Schildkraut JM, Chenevix-Trench G, Berchuck A, Sellers TA; Ovarian Cancer Association Consortium, Australian Cancer Study (Ovarian Cancer); **Australian Ovarian Cancer Study Group**. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev*. 19:600-604. (2010). (IF=4.3)

Verderio P, Pizzamiglio S, Southey MC, Spurdle AB, Hopper JL, Chen X, Beesley J; **Australian Ovarian Cancer Study Group**, KConFab, Schmutzler RK, Engel C, Burwinkel B, Bugert P, Ficarazzi F, Manoukian S, Barile M, Wappenschmidt B, Chenevix-Trench G, Radice P, Peterlongo P. A BRCA1 promoter variant (rs11655505) and breast cancer risk. *J Med Genet*. 47:268-270. (2010). (IF=5.6)

Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, **Australian Ovarian Cancer Study Group**, Sharma R, Stewart C, Fereday S, Caldas C, DeFazio A, Bowtell D and Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *J Pathol*. 221:49-56. (2010). (IF=7.3)

Price MA, Zaccharie R, Butow PN, deFazio A, Chauhan D, Espie CA, Friedlander M, Webb PM, **Australian Ovarian Cancer Study Group**. Australian Ovarian Cancer Study – Quality of Life Study Investigators. Prevalence and predictors of insomnia in women with invasive ovarian cancer. *Eur J Cancer* 45:3262-3270. (2009). (IF=4.8)

Jordan SJ, Green AC, Nagle CM, Olsen CM, Whiteman DW, Webb PM, **Australian Ovarian Cancer Study Group\*** and the Australian Ovarian Cancer Study Group. Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. *Am J Epidemiol*. 170:607-614. (2009). (IF=5.0)

Jordan SJ, Siskind V, Green AC, Whiteman DC, Webb PM, **Australian Ovarian Cancer Study Group**. Breastfeeding and risk of epithelial ovarian cancer. *Cancer Cause Control* 21:109-116. (2009). (IF=3.0)

Dick M-L, Siskind V, Purdie DM, Green AC, **Australian Ovarian Cancer Study Group\***. Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and systematic review. *Cancer Cause Control* 20:1571-1585. (2009). (IF=3.0)

Johnatty SE, Beesley J, Chen X, Spurdie AB, Defazio A, Webb PM, **Australian Ovarian Cancer Study Group\***. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the Ovarian Cancer Association Consortium. *Twin Res Hum Genet*. 12:269–275. (2009). (IF=1.9)

Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Cehn X et al., **Australian Ovarian Cancer Study Group\***. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. *Breast Cancer Res Tr* 117:371-379. (2009). (IF=4.2)

Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallee MP, Voegelé C, Webb PM, Whiteman DC, **Australian Ovarian Cancer Study Group**. Rare, evolutionarily unlikely missense substitutions in 1 ATM confer increased risk of breast cancer. *Am J Hum Genet*. 85:427-446. (2009). (IF=11.0)

Etemadmoghadam D, deFazio A, Beroukhir R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, AOCs Study Group, Harnett P, Lade S, Akslen LA, Tinker A, Locandro B, Alsop K, Chiew Y-E, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB,

Meyerson M, David Bowtell DLL, **Australian Ovarian Cancer Study Group**. Integrated genome-wide copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. *Clin Cancer Res.* 15:1417-1427. (2009). (IF=8.2)

### **(C) Books**

1. **Schwarz VA**. Walter Edwin Griesbach (1888-1968). Life and Work. Medical thesis, 1998. Peter Lang Publishers, European University Publications, 7, Section B: History of Medicine, Vol. 8. 1999. ISDN 3-631-34446-5.

### **(D) Book Chapters**

8. Montavon C, **Heinzelmann-Schwarz V**. Bedeutung der interprofessionellen Praxis in der gynäkologischen Onkologie. Buch: "Interprofessionelle Praxis in der gynäkologischen Onkologie". Hanna Mayer und Beate Senn. 2017.

7. Vetter M, **Heinzelmann-Schwarz V**. Immunotherapy in Gynecologic Cancers. Immunology and Microbiology "Immunotherapy - Myths, Reality, Ideas, Future", Chapter 6, 103-127. 2017

6. Fedier A, Tse W-C, Zanetti Dällenbach R, **Heinzelmann-Schwarz V.A**. Current State of Antibody-based Immunotherapy for Ovarian Cancer. Recent Advances in Obstetrics and Gynaecology. 26(Ch-4):33-46. 2015

5. **Heinzelmann-Schwarz V**. Epithelial ovarian cancer. Malaysian Undergraduate Textbook of Gynaecological Oncology. 2013

4. **Schwarz VA**, Fink D. Importance of photodynamic therapy in the treatment of DNA Mismatch Repair-deficient tumors. In: Fluorescence Diagnostics and Photodynamic Therapy. Shaker Publishers, Aachen 2000.

3. Fehr MK, **Schwarz VA**, Simeon R, Wyss P. Photodynamic therapy of intraepithelial vulvar lesions following topical application of 5-aminolevulinic acid. In: Fluorescence Diagnostics and Photodynamic Therapy. Shaker Publishers, Aachen 2000.

2. Wyss P, Fehr MK, Hornung R, **Schwarz VA**, Haller U. Photodynamic Therapy of Recurrent Breast Cancer. In: Photomedicine in Gynecology and Reproduction. Karger Publishers, Basel 2000.

1. Fehr MK, Wyss P, Dobler D, Chapman CF, Krasieva TB, Tromberg BJ, Tadir Y, **Schwarz VA**, Haller U. Selective Photosensitization in Vulvar Condyloma and PDT of Vulvar Intraepithelial Neoplasia. In: Photomedicine in Gynecology and Reproduction. Karger Publishers, Basel 2000.

### **(E) Talks**

**Heinzelmann-Schwarz, V.A.** Jacobs F, Glycobiology in tumor detection Molecular Medicine - The Molecular Basis of Human Diseases Autumn Semester 2015, Basel/Switzerland, **11.10.2016**

**Heinzelmann-Schwarz, V.A.** The new FIGO IC ovarian cancer classification does not reflect prognosis, 66th Annual Meeting of the Society of Pelvic Surgeons, St. Louis/USA, **04.-08.10.2016**

**Heinzelmann-Schwarz, V.A.** Gynäkologische Tumoren / Ovarialkarzinom, medArt basel 16, Basel/Switzerland, **22.06.2016**

**Heinzelmann-Schwarz, V.A.** Konkrete Einblicke in geförderte Forschungsarbeiten, Einblick in die Krebsforschung an der Frauenklinik des USB, Basel/Switzerland, **26.05.2016**

**Heinzelmann-Schwarz, V.A.** Die Waageschale der onkologischen Therapie beim Eierstockkrebs – wieviel Nutzen ohne Schaden. Aus Sicht einer Patientin, Krebsinformationstag Tumorzentrum, Basel/Switzerland, **23.01.2016**

**Heinzelmann-Schwarz, V.A.** Ringvorlesung: Repetition und Vertiefung Prävention und Diagnostik gynäkologischer Malignome, Themenblock Reproduktion, 2. MA, Basel/Switzerland, **18.12.2015**

**Heinzelmann-Schwarz, V.A.** Multimodale Therapie des Ovarial Carcinoms, Themenblock Reproduktion, 2. MA, Basel/Switzerland, **07.12.2015**

**Heinzelmann-Schwarz, V.A.** Zervix- und Vulva Ca, Kolposkopiekurs, Basel/Switzerland, **31.10.2015**

**Heinzelmann-Schwarz, V.A:** Not the same disease? Distinct molecular profiles define high grade serous ovarian and peritoneal cancer“65th Meeting of the Society of Pelvic Surgeons, San Francisco/USA, **20.10.-23.10.2015**

**Heinzelmann-Schwarz, V.A.** Jacobs F, Glycobiology in tumor detection Molecular Medicine - The Molecular Basis of Human Diseases Autumn Semester 2015, Basel/Switzerland, **06.10.2015**

**Heinzelmann-Schwarz, V.A.** Tumoren des Corpus uteri, Vorstellung von EGONE, Tumoren der Adnexe, Themenblock Reproduktion 3. JK, Basel/Switzerland, **17.04.2015**

**Heinzelmann-Schwarz, V.A.** Ovarialkarzinom: Epidemiologie, Risikofaktoren, Einteilung der Ovarialkarzinome. Ovarialkarzinom: Adjuvante Therapie. Ovarialkarzinom: Nachsorge Tumormarker. Endometriumkarzinom: Operative Therapie. Endometriumkarzinom: Adjuvante Therapie & Nachsorge. Sarkome und Karzinosarkome des Uterus: Eine besondere Herausforderung. Vulvakarzinom: Operative und adjuvante Therapie. Zervixkarzinom: Adjuvante Therapie. Frühjahrsfortbildung SGGG 2015, St. Moritz/Switzerland, **26.03.-29.03.2015**

**Heinzelmann-Schwarz, V.A.** Prävention und Diagnostik gynäkologischer Malignome, Adnexe, Themenblock Reproduktion, 3. JK, Basel/Switzerland, **14.04.2014**

**Heinzelmann-Schwarz, V.A.** Multimodale Therapie des Ovarial Carcinoms,. Themenblock Reproduktion, 2. MA, Basel/Switzerland, **08.12.2014**

**Heinzelmann-Schwarz, V.A.** Tumoren des Corpus uteri, Vorstellung von EGONE, Tumoren der Adnexe, Themenblock Reproduktion, 3. JK, Basel/Switzerland, **14.04.2014**

**Heinzelmann-Schwarz, V.A.** Onkologie in der Frauenheilkunde, Thementag Gen-Medizin, Basel/Switzerland, **27.03.2014**

**Heinzelmann-Schwarz, V.A.** Diagnostik und Behandlung von Adnextumoren, 27. Basler Fortbildungsnachmittag für Gynäkologen und Geburtshelfer, Basle/Switzerland, **20.03.2014**

**Heinzelmann-Schwarz, V.A.** Das Tumorzentrum Universitätsspital Basel: Schliessen sich Schulmedizin und Komplementärmedizin gegenseitig ergänzen? Vorstellungen aus dem gynäkologischen Tumorzentrum, Muba Basel, Basle/Switzerland, **15.02.2014**

**Heinzelmann-Schwarz, V.A.** Change of a Paradigm: Translational Biomarker Research in Ovarian Cancer, Advisory Board Meeting, Basle/Switzerland, **23.02.2014**

**Heinzelmann-Schwarz, V.A.** Walter Edwin Griesbach; Leben und Werk, Seminare Endo/Diab, Basel/Switzerland, **22.01.2014**

**Heinzelmann-Schwarz, V.A.** Krebstherapie am Beispiel des Eierstockkrebses, Liestal/Switzerland, Weltenreise, **09.12.2013**

**Heinzelmann-Schwarz V.A.:**Krebstherapie am Beispiel des Eierstockkrebses, Weltenreise, Basle/Switzerland, **15.11.2013**

**Heinzelmann-Schwarz, V.A.** Molekularbiologische und konventionelle Laboruntersuchungen zur Rationalisierung der Ovarialkarzinom-Pflege. Berner Kolloquium für Labormedizin, Liebefeld/Switzerland, **29.10.2013**

**Heinzelmann-Schwarz, V.A.** "Vorgehen bei Adnexbefunden während/ausserhalb der Schwangerschaft. Schwangerschafts-Ultraschall-Grundkurs, Basle/Switzerland, **19.10.2013**

**Heinzelmann-Schwarz, V.** Research in Australia. Foundation Meeting of the German-Australian Society. Biannual Meeting of the German Society of Gynaecologists and Obstetricians, Munich, Germany, **09.-13.10.2012**

**Heinzelmann-Schwarz, V.,** Jacob, F., Goldstein, D., Bovin, N, Fink, D, Huflejt, M. (2010). Anti-glycan antibodies as new ovarian cancer tumormarkers identified using printed glycan array. Biennial Meeting of the International Society of Gynaecological Oncology, Prague, Czech Republic, **22.-26.10.2010.**

**Heinzelmann-Schwarz, V A.** Anti-glycan antibodies as ovarian tumormarkers identified using printed glycan array. Annual Meeting of the Australian Society for Gynaecological Oncology. Perth, **23.03.2010.**

**Heinzelmann-Schwarz, V. A.** New trends in ovarian cancer diagnosis and treatment. Inaugural Lecture as Privatdozent (Assistant Professor) at the University of Zurich, Zurich/Switzerland, **20.09.2008**

**Heinzelmann-Schwarz, V. A.** SFRP4 is a key regulator of the Wnt Signaling pathway and a diagnostic marker in endometrioid cancers and endometriosis. Australasian Society of Gynaecologic Oncologists (ASGO), National Conference, Hobart/Australia, **08.05.2008.**

**Heinzelmann-Schwarz, V.** Transcriptomics in ovarian cancer. IfBMB-Seminar, Institute for Biochemistry and Molecular Biology, University of Bern/Switzerland, **18.11.2004.**

**Heinzelmann-Schwarz, V.** Molecular profiling of epithelial ovarian cancer. Monday Research Meeting, Institute for Clinical Pathology, University Hospital Zurich/Switzerland, **08.11.2004.**

**Heinzelmann-Schwarz, V.** Transcription profiling of epithelial ovarian cancers. Basic Science Meeting for Gynaecological Oncology, Gynaecological University Hospital, Basel/Switzerland, **14.10.2004.**

**Heinzelmann-Schwarz, V.,** Gardiner-Garden, M., Henshall, S.M., Scolyer, R.A., Leung, K.-C., Scurry, J., Smith, A.N., Sutherland, R.L., O'Brien, P.M., Hacker, N.F. Reduced expression of SOCS3 predicts poor outcome in epithelial ovarian cancer. International Gynecologic Cancer Society (IGCS), 10th Biennial Meeting, Edinburgh/UK **26.09.2004.**

**Heinzelmann-Schwarz, V.**, Scolyer, R., Scurry, J., Gardiner-Garden, M., Smith, A., Sutherland, R., Hacker, N., O'Brien, P. Galectin4 and Meprin Alpha are biomarkers for mucinous ovarian tumors. 19<sup>th</sup> Meeting of the Australian Society of Gynaecological Oncologists (ASGO), Singapore **20.04.2004**.

**Heinzelmann-Schwarz, V.**, Gardiner-Garden, M., Henshall, S., Gish, K., Scurry, J., Scolyer, R., Hacker, N., O'Brien, P., Sutherland, R.L. Interstudy Comparison Of Gene Expression Profiles Identifies Tumour Markers Of Epithelial Ovarian Cancer. 42<sup>nd</sup> Australian Society for Medical Research (ASMR) National Scientific Conference, Adelaide/Australia **2003**.

**Heinzelmann-Schwarz, V.**, Gardiner-Garden, M., Henshall, S., Gish, K., Scurry, J., Scolyer, R., Hacker, N., O'Brien, P., Sutherland, R.L. Interstudy validation of gene expression profiles identifies candidate biomarkers of epithelial ovarian cancer. Australian Society for Medical Research (ASMR) Scientific Meeting Sydney/Australia **2003**.

**Schwarz, V.A.**, Fedier, A., Haller, U., Fink, D. The importance of DNA Mismatch Repair-Mutations in the therapy of breast cancer. Swiss Society for Gynaecologists and Obstetricians (SGGG), Annual Meeting, Lugano/Switzerland **2000**.

**Schwarz, V.A.**, Fink, D. The importance of Photodynamic Therapy in the treatment of DNA Mismatch Repair-deficient cells. Marburger LASER-Symposium, Marburg/Germany **1999**.

**Schwarz, V.A.**, Walt, H., Haller, U., Fink, D. Loss of DNA mismatch repair does not result in resistance to photodynamic therapy. 8<sup>th</sup> Congress European Society for Photobiology in Granada, Granada/Spain **1999**.

## **(F) Invited Lectures**

**Heinzelmann-Schwarz, V.A.** Glycobiology in tumor detection, Molecular Medicine – The Molecular Basis of Human Diseases Autumn Semester 2017, Department of Biomedicine, Universitätsspital Basel/Switzerland, **07.11.2017**

**Heinzelmann-Schwarz, V.A.** Ovarial- und Endometriumkarzinom – Tumorbilogie adaptierte Therapiestrategien, big surgery for bad biology, Frauenklinik Universitätsspital Basel/Switzerland, **19.10.2017**

**Heinzelmann-Schwarz, V.A.** Position of PARP in clinical practice, 10 jours Cancer de l'Ovaire, Hôpitaux Universitaire de Genève/Switzerland, **28.09.2017**

**Heinzelmann-Schwarz, V.A.** Endokrine Therapieoptionen bei gynäkologischen Karzinomen; Moderne Entwicklungen, Gynäkologie Update Refresher, Technopark, Zürich/Switzerland, **17.05.2017**

**Heinzelmann-Schwarz, V.A.** Tumoren des Corpus uteri und der Adnexe, Vorstellung EGONE, Themenblock Reproduktion 3. BA, FS 2017, Schaffhausen/Switzerland, **10.04.2017**

**Heinzelmann-Schwarz, V.A.** Personalisierte Medizin – Was bedeutet das?, Krebs-Infotag Tumorzentrum Universitätsspital Basel, **04.02.2017**

**Heinzelmann-Schwarz, V.A.** Distinguished Clinicians in Oncology, CHUV centre hospitalier universitaire vaudois, Oncology Department, Haematology Unit, Lausanne/Switzerland, **27.01.2017**

**Heinzelmann-Schwarz, V.A.** Risikofaktoren und familiäre Neigung – was uns die Gene zeigen, Aktuelles zur Behandlung von Brustkrebs – fachübergreifend und individuell – Vortragsreihe der Klinik für Strahlentherapie und Radioonkologie für Patient/innen und Interessierte, Basel/Switzerland, **09.06.2016**

**Heinzelmann-Schwarz, V.A.** Borderline-Tumore des Ovars „Empfehlungen zur präoperativen Diagnostik und Therapieberatung, Kongress „Gynäkologie Update-Refresher“, Zürich/Switzerland, **26.-28.05.2016**

**Heinzelmann-Schwarz, V.A.** Management postmenopausaler Frauen, Ärzte-Nachmittag Privatklinik Obach, Solothurn/Switzerland, **28.01.2016**

**Heinzelmann-Schwarz, V.A.** Wieviele Gynäkoonkolgen braucht die Schweiz? Chefärztekongferenz – Herbstsitzung, Bern/Switzerland, **03.12.2015**

**Heinzelmann-Schwarz, V.A.** Not the same disease? Transcriptome and glycome profile comparison of high grade serous ovarian and peritoneal cancer, The fourth annual Health-Science Alliance symposium, Randwick/Australia, **16.-21.11.2015**

**Heinzelmann-Schwarz, V.A.** Anti-angiogenetische Therapien von Ovarialkarzinomen, DGHO Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Basel/Switzerland, **09.-13.10.2015**

**Heinzelmann-Schwarz, V.A.** Therapiekonzepte beim Ovarialkarzinom - Altes und Neues. Kantonsspital AG, Aarau/Switzerland, **20.08.2015**

**Heinzelmann-Schwarz, V.A.** Ovarialkarzinom: Die Gratwanderung zur Verringerung der Morbidität und Mortalität, 2. Luzerner Symposium für Gynäkologische Onkologie, Luzern/Switzerland, **28.05.2015**

**Heinzelmann-Schwarz, V.A.** Zystadenom - Borderline – Karzinom, Gynäkologie - Update Refresher, Zürich/Switzerland, **12.05.2015**

**Heinzelmann-Schwarz, V.A.** Tumormarker in der Gynäkologie, Vortragsreihe WIND zur Fortbildung für diplomierte Biomedizinische Analytikerinnen und Akademiker aus der Klinischen Chemie und externe Laboratorien, Basel/Switzerland, **07.05.2015**

**Heinzelmann-Schwarz, V.A.** Die universitäre Weiterbildung aus Sicht der Subspezialistin, 66. Geschäftssitzung der Schweizerischen Gynäkologischen Chefärztekongferenz, Bern/Switzerland, **04.12.2014**

**Heinzelmann-Schwarz, V.A.** Tumornachsorge in der Praxis, 17. Ostschweizer Symposium für praktische Gynäkologie und Geburtshilfe, Näfels/Switzerland, **13.11.2014**

**Heinzelmann-Schwarz, V.A.** Session AGE: Ovarialtumore: neue Aspekte der Diagnostik und Therapie: Vortrag: „Bei laparoskopischer Zystektomie, wann ist eine gleichzeitige Salpingektomie indiziert?“ SGGG, Annual Meeting, Interlaken/Switzerland **25.-27.06.2014**.

**Heinzelmann-Schwarz, V.A.** Special topic Gynäkologie: „Tumormarker“, medArt Basel, **23.-27.06.2014**

**Heinzelmann-Schwarz, V.A.** Ovarial- und Zervixkarzinom: Neuerungen in der Diagnostik- und Therapieempfehlungen – warum kann länger besser wirken? Gynäkologie – Update Refresher, Baden/Switzerland, **17.05.2014**.

**Heinzelmann-Schwarz, V.A.** Ovarian cancer in BRCA mutation carriers, 14th World Congress on Menopause, Cancun/Mexico, **01.-04.05.2014**

**Heinzelmann-Schwarz, V.A.** Onkologie in der Frauenheilkunde, Thementag Gen-Medizin, Basel/Switzerland, **27.03.2014**

**Heinzelmann-Schwarz, V.A.** Diagnostik und Behandlung von Adnextumoren, 27. Basler Fortbildungsnachmittag für Gynäkologen und Geburtshelfer, Basel/Switzerland, **20.03.2014**

**Heinzelmann-Schwarz, V.A.** "Sarkome des Uterus". 48. Jahresfortbildungsveranstaltung der Frauenklinik Universitätsspital Basel Basel/Switzerland, **29.08.2013**

**Heinzelmann-Schwarz, V.A.** "The role of ultrasound for the diagnosis and therapeutic management of adnexal masses". Symposium on Ultrasound in Gynecology and Obstetrics. Basel/Switzerland, **13.04.2013**

**Heinzelmann-Schwarz, V.A.** "Ovarian cancer treatment – still the same? " New Women's Hospital, Luzern, Switzerland **11.04.2013**

**Heinzelmann-Schwarz, V. A.** "Research in Australia compared to Switzerland". Swiss Ovarian Cancer Advisory Board, Zurich/Switzerland, **15.11.2012**

**Heinzelmann-Schwarz, V.A.** „Sweet wine in an old bottle; play sugars a role in gynaecological cancers?“ Inaugural Lecture at the University of Basel/Switzerland, **08.11.2012**

**Heinzelmann-Schwarz, V.A.** "Hormonal influence on cervical dysplasia". First Cervical Cytology Symposium: Cervical cytology – a success model. Pfäffikon/Switzerland, **06.09.2012**

**Heinzelmann-Schwarz, V.A.** "BRCA mutations and ovarian cancer – the good, the bad and the ugly". Wolper Jewish Hospital and National Council for Jewish Women, Cancer Awareness Week, Sydney/Australia, **04.10.2011**

**Heinzelmann-Schwarz, V.A.** „Tumormarkers in Ovarian Cancer“. Symposium for the Professorship of Gynaecology, University Hospital Basel/ Switzerland;**06.12.2010.**

**Heinzelmann-Schwarz, V.A.** „Walter Edwin Griesbach. Life and Work“. Founder's Lecture 2009, Auckland Medical History Society, Auckland/New Zealand, 01.10.2009

**Heinzelmann-Schwarz, V.A.** "Cancer Awareness – BRCA gene mutations and ovarian cancer". National Council for Jewish Women, Cancer Awareness Week, Sydney/Australia, **19.10.2008**

## **(G) Further Publications**

9. **Heinzelmann V, Vetter M**, Highlights zu den Genitalkarzinomen der Frau: Ein Kongress mit «practice-changing decisions» Leading Opinions *Hämatologie & Onkologie* 4/16: 124-127

8. **Heinzelmann V, Vetter M** Leading Opinions, Highlights zu den Genitalkarzinomen der Frau Ein Kongress mit „practice-changing decisions“, *Hämatologie & Onkologie* 4/16, 22-25

7. Vetter M, **Heinzelmann-Schwarz V**, Chemotherpaie bei gynäkologischen Tumoren, Update – aktuelle Therapiemöglichkeiten. *info@gynäkologie*, 05\_2015, 20-22 (2015)

6. Vetter M, **Heinzelmann-Schwarz V**, Studienübersicht der Therapieoptionen, Chemotherapie und neue Substanzen beim epithelialen Ovarialkarzinom (EOC), *info@gynäkologie* 02\_2015, 16-20 (2015)

5. **Heinzelmann-Schwarz V, Vetter M**, Aggressive Zytoreduktion – Plädoyer für eine angepasste Therapie. *Hämatologie & Onkologie* 6/15, 72-75 (2015)

4. **Heinzelmann-Schwarz V**, Trost N, Patientinnen-mit-gynaekologischen-Tumoren-gemeinsam-betreuen. *Ars Medici* 18, 2015, 852-854 (2015)
3. Vetter M, **Heinzelmann-Schwarz V**, Platinresistentes Rezidiv bei 39-jähriger Patientin mit metastasiertem serösem Tubenkarzinom. *Aktuell Onkologie*, 9-11 (2015)
2. **Heinzelmann-Schwarz V**, Neuigkeiten im Bereich der gynäkologischen Karzinome, *Hämatologie & Onkologie* 4/14, 144-147 (2014)
1. **Heinzelmann-Schwarz V**, Das Ovarialkarzinom, Diagnostisches und therapeutisches Vorgehen heute, *Schweizer Zeitschrift für Onkologie* 4/2013, 10-13 (2013)



Basel, 24.04.2018